偏弱 趋势方向 主力成本分析 海尔生物688139 时间: 2025年6月24日星期二 40.66分综合得分 30.50 元 当日主力成本 30.11 元 5日主力成本 30.58 元 20日主力成本 31.54 元 60日主力成本 周期内涨跌停 过去一年内该股 涨停 0次 跌停 0 次 北向资金数据 | 持股量1693.16万股 | 占流通比5.32% | | --- | --- | | 昨日净买入-51.00万股 | 昨日增仓比-0.16% | | 5日增仓比-0.757% | 20日增仓比-2.411% | 技术面分析 30.78 短期压力位 29.83 短期支撑位 31.36 中期压力位 29.65 中期支撑位 目前短线趋势不慎明朗，静待主力资金选择方向； 目前中期趋势不慎明朗，静待主力资金选择方向 K线形态 暂无特殊形态 资金流数据 2025年06月24日的资金流向数据方面 | 主力资金净流入502.41万元 | | --- | | 占总成交额8% | | 超大单净流出103.97万元 | | 大单净流入606.38万元 | | 散户资金净流出115.86万 | 关联行业/概念板块 医疗器械 1.4 ...

Group 1 - The stock of Haier Biomedical (688139) has a comprehensive score of 42.72, indicating a weak performance [1] - The main cost analysis shows that the current main cost is 30.07 CNY, with a 5-day main cost of 30.55 CNY and a 20-day main cost of 31.69 CNY [1] - There have been no instances of the stock hitting the upper limit in the past year, and it has also not hit the lower limit [1] Group 2 - The short-term pressure level is at 31.36 CNY, while the short-term support level is at 30.28 CNY [2] - The stock price has broken below the short-term support level, suggesting a cautious approach in the short term [2] - The MACD indicator has formed a golden cross signal, indicating potential upward momentum for certain stocks [3]